Atıf İçin Kopyala
Vural S., Genc D. B., Kebudi R., Dogan O., Karaman S.
TURKISH JOURNAL OF PEDIATRICS, cilt.63, sa.4, ss.639-647, 2021 (SCI-Expanded)
-
Yayın Türü:
Makale / Tam Makale
-
Cilt numarası:
63
Sayı:
4
-
Basım Tarihi:
2021
-
Doi Numarası:
10.24953/turkjped.2021.04.011
-
Dergi Adı:
TURKISH JOURNAL OF PEDIATRICS
-
Derginin Tarandığı İndeksler:
Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, TR DİZİN (ULAKBİM)
-
Sayfa Sayıları:
ss.639-647
-
Anahtar Kelimeler:
Burkitt lymphoma, BFM, methotrexate, NON-HODGKIN-LYMPHOMA, HIGH-DOSE METHOTREXATE, B-CELL MALIGNANCIES, CHILDREN, CHEMOTHERAPY, ADOLESCENTS, EXPERIENCE, CHILDHOOD, THERAPY, INVOLVEMENT
-
İstanbul Üniversitesi Adresli:
Evet
Özet
Background. Chemotherapy with high dose methotrexate is the mainstay of treatment for Burkitt lymphoma (BL), especially to manage central nervous system (CNS) disease. However, methotrexate administration requires close drug level monitoring for appropriate folinic acid rescue, which might not be readily available in all centers. In this study, we assessed the long-term treatment outcomes of a modified Non-Hodgkin lymphoma (NHL)-Berlin-Frankfurt-Munster (BFM) 90 regimen in pediatric high-risk BL without CNS involvement.